The objective of this study was to directly compare the safety of tocilizumab (TCZ) and TNF inhibitors (TNFIs) in rheumatoid arthritis (RA) patients in clinical practice.
Via Krishan Maggon
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Your new post is loading...
Your new post is loading...
Krishan Maggon 's curator insight,
March 16, 2015 1:18 PM
The BMJ Today reports the results of an open label pragmatic trial—the TACIT trial—that compared the impact on disability at 12 months of a TNF based strategy (as recommended by the National Institute for Health and Care Excellence) versus a combined disease modifying drug strategy, which includes methotrexate. In this study, the combination of older drugs was non-inferior to the biologic agents. In a related editorial, Pierre Miossec concludes that the TACIT trial “gives fresh hope to more patients around the world that they can achieve equal or better disease control with combinations of established, low cost, and easy to produce alternatives [to the more expensive newer biologics].” |
Krishan Maggon 's curator insight,
March 16, 2015 1:30 PM
Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial
BMJ 2015; 350 doi: http://dx.doi.org/10.1136/bmj.h1046 (Published 13 March 2015)Cite this as: BMJ 2015;350:h1046 |
Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry
Ryoko Sakai†, Soo-Kyung Cho†, Toshihiro Nanki, Kaori Watanabe, Hayato Yamazaki, Michi Tanaka, Ryuji Koike, Yoshiya Tanaka, Kazuyoshi Saito, Shintaro Hirata, Koichi Amano, Hayato Nagasawa, Takayuki Sumida, Taichi Hayashi, Takahiko Sugihara, Hiroaki Dobashi, Shinsuke Yasuda, Tetsuji Sawada, Kazuhiko Ezawa, Atsuhisa Ueda, Takao Fujii, Kiyoshi Migita, Nobuyuki Miyasaka, Masayoshi Harigai* and for the REAL Study Group
*Corresponding author: Masayoshi Harigai mharigai.mpha@tmd.ac.jp
† Equal contributors
Author Affiliations
For all author emails, please log on.
Arthritis Research & Therapy 2015, 17:74 doi:10.1186/s13075-015-0583-8
Ryoko Sakai and Soo-Kyung Cho contributed equally to this work.
Published: 23 March 2015